Introduction
Acute myeloid leukemia (AML) is a disease characterized by the rapid proliferation of immature myeloid cells in the bone marrow resulting in dysfunctional hematopoiesis 1 . Although standard induction chemotherapy can induce complete remissions, many patients eventually relapse and succumb to the disease 2 . Therefore, the development of novel therapeutics for AML is crucial. Recent advances in the immunophenotyping of AML cells have revealed several AML associated cell surface antigens that may act as targets for future therapies 3 . Indeed, pre-clinical investigations using antibodies targeting CD44, CD47, T cell immunoglobulin mucin-3 (TIM-3) and the interleukin 3 receptor alpha chain (IL-3Rα; CD123) for the treatment of AML have been described and demonstrated promising anti-leukemic activity in murine models 3, 4 .
Additionally, two phase I trials for CD123-specific therapeutics have been completed with both drugs displaying good safety profiles (ClinicalTrials.gov ID: NCT00401739 and NCT00397579). Unfortunately, these CD123 targeting drugs had limited efficacy suggesting that alternative, and more potent therapies targeting CD123 may be required to observe anti-leukemic activity.
A possibly more potent alternative therapy for the treatment of AML is the use of T cells expressing chimeric antigen receptors (CARs) that redirect T cell specificity towards cell surface tumor associated antigens (TAAs) in an MHC-independent manner 5 . In most cases, CARs consist of a single-chain variable fragment (scFv) from a monoclonal antibody fused to the signaling domain of CD3ζ and may contain a costimulatory endodomain 5 . Several groups have developed CARs targeting various antigens for the treatment of B-cell malignancies [6] [7] [8] [9] [10] and many have gone on to evaluating CAR expressing T cells in phase I clinical trials [11] [12] [13] [14] [15] . In contrast, CAR engineered T cells for the treatment of AML remain scarce [16] [17] [18] .
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Materials and Methods

Colony Forming Cell Assay
CD34
+ cells from cord blood (CB) mononuclear cells or primary AML samples were selected using immunomagnetic column separation (Miltenyi Biotech). 1x10 3 CD34+
cord blood cells or 5x10 3 CD34+ primary AML patient cells are co-cultured for 4 hours with 2.5x10 4 or 1.25x10 5 CAR + T cells, respectively. At the end of the 4 hour co-culture, the entire cell mixture was transferred to a methylceullose based growth medium and plated in duplicate 20 . 14 to 18 days later, colony-forming unit granulocyte-macrophage (CFU-GM) and burst-forming unit erythroid (BFU-E) colonies were enumerated. To normalize, the average colony number from CD19R-treated samples (n=3) was set at 100% and the values from the other groups were adjusted using the following calculation: 21 . Survival curves were constructed using Kaplan-Meier method and statistical analyses of survival were performed using Log-rank (Mantel-Cox) tests with P < 0.05 considered significant.
Statistics analysis
Statistical analyses were performed using Graphpad Prism v5.04. Unpaired Student's t-test were used to identify significant differences between treatment groups.
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Generation of CD123 CAR expressing T cells
To redirect T cell specificity, we developed lentiviral vectors encoding CD123 CARs. Each of the CARs consists of codon-optimized sequences encoding one of two CD123-specific scFvs, 26292 and 32716, which bind distinct epitopes and have similar binding affinities (3.5 and 1.4nM apparent affinities on CD123 + TF-1 cells, respectively 19 ) for CD123. The scFvs are fused in-frame to the human IgG4 Fc region, a CD28 costimulatory domain, and the CD3ζ signaling domain. Just downstream of the CAR sequence is a T2A ribosome skip sequence and a truncated human EGFR (EGFRt) transduction marker ( Figure 1A ). OKT3 stimulated PBMCs from healthy donors were lenti-transduced and CAR expressing T cells were isolated by immunomagnetic selection using a biotinylated-Erbitux antibody followed by a secondary stain with antibiotin magnetic beads. Informed consent was obtained in accordance with the Declaration of Helsinki and the PBMCs were obtained under institutional review board approved protocols. Following one REM cycle, the isolated cells were analyzed by flow cytometry for CAR surface expression and T-cell phenotype. Both Fc and EGFRt expression was greater than 90% in the generated T cell lines from three healthy donors and final T cell products consisted of a mixture of CD4 and CD8 positive T cells ( Figure   1B , 1C).
CD123 CAR T cells specifically target CD123 expressing tumor cell lines
To confirm the specificity of our CD123 CAR T cells, we examined the ability of the genetically modified T cells to lyse 293T cells transiently transfected to express CD123 (293T-CD123; Figure 2A ). Both CD123 CAR T cells generated efficiently lysed 293T-CD123, but not 293T cells transiently transfected to express CD19, demonstrating the specific recognition of CD123 ( Figure 2B ). We next investigated the in vitro cytolytic Figure 2G ). Similar results were observed using E:T ratios of 1:1 and 2:1 (data not shown).
CD123 CAR T cells activate multiple effector functions when cocultured with primary AML samples
The over-expression of CD123 on primary AML samples is well documented [22] [23] [24] and confirmed in our study ( Figure S1 and Table 2 ). Multifaceted T cell responses are critical for robust immune responses to infections and vaccines and may also play a role in the anti-tumor activity of CAR redirected T cells 25 . To investigate the ability CD123
CAR T cells to activate multiple effector pathways against primary AML samples, engineered T cells were cocultured with three different AML patient samples (179, 373, and 605) for 6 hours and evaluated for upregulation of CD107a and production of IFN-γ and TNF-α using polychromatic flow cytometry (gating strategy shown in Figure S2 ). We observed cell surface mobilization of CD107a in both the CD4 and CD8 compartments of 
CD123 CAR expressing T cells target primary AML cells in vitro
To evaluate the ability of CD123-specific T cells to kill primary AML cells, we Figure S4 ).
CD123-specific T cells do not eliminate colony formation by cord blood cells in vitro
Given that CD123 is expressed on common myeloid progenitors (CMPs) 26 , we investigated the effect of our engineered T cells on the colony forming ability of CD34- is expressed on a subset of T cells making it a non-ideal target for a CAR based therapy 38 . Additionally, the anti-leukemic activity of CD33-targeting therapies was often accompanied with slow recovery of hematopoiesis and cytopenias likely the result of CD33 expression on long-term self-renewing normal hematopoietic stem cells (HSCs) 39 .
Further, hepatotoxicities are a common side effect of CD33-targeted treatments and are possibly due to the unintended targeting of CD33 + Kupffer cells 40 .
While 11, 12, 14 .
Here, we demonstrate the functionality of CD123-CAR expressing T cells by analyzing the upregulation of CD107a, production of inflammatory cytokines and proliferation of CD123-specific T cells in response to both CD123 + cell lines and primary AML samples.
While CD123 CAR T cells proliferated in response to CD123 + target cells, this proliferation was limited and likely due to the CD123 CAR T cells going through multiple rounds of rapid expansion protocol prior to being used in the proliferation assays.
Importantly, we observed multi-functionality in subsets of both the CD4 + and CD8 + compartments, which may promote sustained anti-leukemic activity and boost antileukemic activity within the tumor microenvironment 42 . Although polyfunctionality was modest and observed in a subset of CD123 CAR T cells, the inclusion of other costimulatory domains such as 4-1BB, and the use of "younger" less differentiated T cells may further augment CD123 CAR responses and are an area of active research 8, 43 .
For , we recognize that further experimentation is needed to characterize the potential impact on long term hematopoiesis that CD123 CAR T cells may have. In order to control unwanted offtarget toxicities, we have included EGFRt in our lentiviral construct to potentially allow for ablation of CAR expressing T cells 44 . Other strategies to modulate CAR T cell activity such as the inducible caspase 9 apoptosis switch 45 or electroporation of mRNA to allow for transient CAR expression 46 are also of high interest. Additionally, an ideal setting for the use of autologous CD123 CAR T cells clinically may be in the context of allogeneic HSCT where a compatible stem cell donor has been identified prior to infusion of CAR T cells. A similar treatment plan has been used successfully to treat acute lymphoblastic leukemia patients with CD19 CAR T cells 47 .
Significantly, we demonstrate that cryopreserved PBMCs from AML patients with active disease can be genetically modified to express CD123 CARs and exhibit potent cytolytic activity against autologous leukemic blasts in 2/3 samples we examined. While Further, we demonstrate that T cells derived from AML patients can be genetically modified to express CD123-specific CARs and lyse autologous blasts in vitro. Finally, we demonstrate that our CD123 CAR T cells exhibit potent anti-leukemia effects in vivo.
Therefore, CD123 CAR T cells are a promising candidate for future immunotherapy of AML. 
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